TL;DR
This study investigated how two HER2-targeting drugs, trastuzumab and afatinib, affect signaling pathways in gastric cancer cells. They found that afatinib consistently impacts HER kinases and downstream pathways, suggesting its potential use regardless of HER2 activation status, while trastuzumab's effectiveness is highly dependent on HER2 activation and doesn't significantly alter downstream signaling.
What Problem Does This Paper Address?
Gastric cancer remains a significant global health challenge with a poor prognosis, despite advances in treatment. While HER2-targeted therapies like trastuzumab have shown promise, their exact molecular mechanisms and the reasons for treatment resistance are not fully understood. Specifically, how trastuzumab directly impacts the complex network of signaling proteins (kinases) within cancer cells, and how it compares to other HER-targeting drugs like afatinib, is an open question. This paper aims to dissect these molecular effects to better understand drug efficacy and identify potential resistance mechanisms.
Methods
The researchers employed a multi-pronged approach:
- Proteome Profiling: This was the core technique. They used specialized arrays (Proteome Profiler Phospho-RTK Array and Phospho-Kinase Array) to simultaneously measure the phosphorylation status of a large number of receptor tyrosine kinases (RTKs) and intracellular kinases. Phosphorylation is a key mechanism for activating or deactivating these proteins, thus controlling cellular signaling.
- Western Blotting: Used to validate specific protein phosphorylation changes observed in the proteome profiler arrays and to examine protein expression levels.
- Cell Proliferation Assays (WST-1): To assess the functional outcome of drug treatment on cancer cell growth.
- Immunohistochemistry (IHC): To determine the HER2 status of the cell lines used.
- Statistical Analysis: Employed mixed models and clustering to analyze the complex proteomic data, identify significant changes, and group similar responses.
Datasets
The study utilized three human gastric cancer cell lines: NCI-N87, MKN1, and MKN7, chosen for their varying HER2 expression levels. An additional cell line, Hs746T, known for MET amplification, was also included to investigate resistance mechanisms. The data generated from the proteome profiler arrays and proliferation assays constitute the primary datasets analyzed.
Key Insights and Ideas
- Afatinib's Broad Impact: Unlike trastuzumab, afatinib consistently affects HER family kinases and their downstream signaling pathways across different cell lines, regardless of HER2 activation status. This suggests a more robust mechanism of action.
- Trastuzumab's Context-Dependency: Trastuzumab's effectiveness is highly dependent on the presence of activated HER2. Its effects are not consistently seen across all cell lines, and importantly, it doesn't appear to significantly alter downstream intracellular kinase activity.
- MET Amplification as a Resistance Factor: The study identified MET amplification as a potential mechanism of resistance to afatinib, as demonstrated by the lack of response in the MET-amplified Hs746T cell line.
- Discrepancies in Detection: The paper highlights potential discrepancies between western blot (detecting specific phosphorylation sites) and proteome profiler arrays (detecting multiple sites or total proteins), emphasizing the importance of using complementary techniques.
Key Results
- RTK Phosphorylation: Proteome profiling revealed that trastuzumab, afatinib, and EGF/NRG1 primarily influenced HER family RTKs. Trastuzumab showed a significant reduction in HER2 phosphorylation in NCI-N87 cells but had less impact on MKN1 and MKN7. Afatinib consistently reduced EGFR and HER3 phosphorylation.
- Downstream Kinase Activity: Trastuzumab monotherapy did not show a measurable effect on downstream kinase phosphorylation in any of the tested cell lines. In contrast, afatinib treatment, alone or in combination with trastuzumab, consistently affected downstream kinases like ERK1/2, AKT1/2/3, and WNK1.
- Proliferation Inhibition: Afatinib significantly reduced the proliferation of NCI-N87, MKN1, and MKN7 cells. Trastuzumab showed a slight, non-significant decrease in NCI-N87 proliferation. The combination of afatinib and trastuzumab was as effective as afatinib alone.
- Afatinib Non-responder: The Hs746T cell line, with MET amplification, showed no significant response to afatinib treatment, suggesting MET amplification as a resistance mechanism.
Limitations and Future Work
- In Vitro vs. In Vivo: The study was conducted using cell lines in vitro. The authors acknowledge that in vivo effects, such as antibody-dependent cell-mediated cytotoxicity (ADCC) for trastuzumab, were not investigated but are relevant for clinical efficacy.
- Limited Cell Lines: While three cell lines were used for detailed analysis, a broader panel could provide more comprehensive insights.
- Clinical Relevance of MET Amplification: While MET amplification was identified as a potential resistance factor in vitro, its clinical relevance for afatinib therapy in gastric cancer needs further investigation.
- Broader Kinase Screening: The authors suggest a broader screening of downstream kinases to identify those affected by trastuzumab, which could reveal novel therapeutic targets.
- Investigating Resistance Mechanisms: Further research is needed to fully elucidate the resistance mechanisms to afatinib, particularly concerning MET amplification.
Summary updated